Use of a Synthetic Cannabinoid in a Correctional Population for Posttraumatic Stress Disorder–Related Insomnia and Nightmares, Chronic Pain, Harm Reduction, and Other Indications

Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks

(2013) Matthew N. Hill et al.   PSYCHONEUROENDOCRINOLOGY

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials

(2011) Mary E. Lynch et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Chronic Medical Conditions among Jail Detainees in Residential Psychiatric Treatment: A Latent Class Analysis

(2011) James A. Swartz   JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE

The abuse potential of the synthetic cannabinoid nabilone

(2010) Mark A. Ware et al.   ADDICTION

Substitution Profile of the Cannabinoid Agonist Nabilone in Human Subjects Discriminating Δ9-Tetrahydrocannabinol

(2010) Joshua A. Lile et al.   CLINICAL NEUROPHARMACOLOGY

The Use of a Synthetic Cannabinoid in the Management of Treatment-Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)

(2009) George A. Fraser   CNS Neuroscience & Therapeutics

Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures — A short review

(2008) I SVIZENSKA et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR